# Tavapadon as Adjunctive Therapy for Parkinson Disease - TEMPO-3 Trial

Page: https://stenobird.com/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/tavapadon-as-adjunctive-therapy-for-parkinson-disease-tempo-3-trial
Text version: https://stenobird.com/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/tavapadon-as-adjunctive-therapy-for-parkinson-disease-tempo-3-trial.md
Podcast: [Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology](https://stenobird.com/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980)
Published: 2026-05-24T16:15:34+00:00
Episode link: https://podcasters.spotify.com/pod/show/amer-ghavanini/episodes/Tavapadon-as-Adjunctive-Therapy-for-Parkinson-Disease---TEMPO-3-Trial-e3jr15e
Audio file: https://anchor.fm/s/ff5a3958/podcast/play/120472174/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-24%2F0f51477e-41bb-9b98-c158-1436898f7771.m4a
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/episodes/tavapadon-as-adjunctive-therapy-for-parkinson-disease-tempo-3-trial
Duration seconds: 970

## Resource

The provided sources detail phase 3 clinical trial results for tavapadon , a novel, once-daily dopamine D1/D5 receptor agonist designed to treat Parkinson disease . In the TEMPO-1 study, fixed doses of the medication significantly improved motor function and daily living experiences for patients in the early stages of the disease. Simultaneously, the TEMPO-3 trial demonstrated that tavapadon effectively increases "good-on-time" and reduces daily "off-time" when used as an add-on therapy for patients experiencing fluctuations while on levodopa . Researchers observed that the drug's selective targeting of specific receptors aims to minimize the side effects , such as hallucinations or impulse control issues, often linked to traditional dopamine agonists. Across both studies, tavapadon maintained a favorable safety profile , with most adverse events being mild to moderate in severity. These findings suggest that tavapadon offers a clinically meaningful new option for managing symptoms throughout different phases of the condition.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/episodes/tavapadon-as-adjunctive-therapy-for-parkinson-disease-tempo-3-trial/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/weekly-neurology-deep-dive-a-review-of-recent-impactful-publications-in-the-field-of-neurology-7345980/tavapadon-as-adjunctive-therapy-for-parkinson-disease-tempo-3-trial.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.